CAMP shows massive 157% increase in outstanding shares (20.1M to 51.9M) coupled with a 55% deterioration in net losses and 362% spike in total liabilities, indicating significant dilution and financial stress despite improved cash position.
The dramatic share dilution suggests CAMP raised capital through equity financing, which explains the higher cash balance but severely dilutes existing shareholders. The company's shift from broad platform language to specific focus on CMP-002 for SYNGAP1 disorder indicates a strategic pivot to a lead candidate approach, likely to preserve cash runway given the mounting losses.
CAMP's financials reveal a company that raised significant capital (cash up 71% to $109.5M) but at the cost of massive shareholder dilution and deteriorating fundamentals - net losses worsened 55% to $80.4M while total liabilities spiked 362% to $70.1M. Despite revenue growing 436% to $3.5M and operating cash flow improving 35%, the company's equity base eroded 24% due to the dilutive financing, creating a mixed picture of improved liquidity offset by substantial shareholder value destruction. The overall financial trajectory suggests an early-stage biotech burning through cash rapidly while attempting to fund operations through dilutive equity raises.
Strong top-line growth of 436.5% — accelerating demand or successful expansion into new markets.
Liabilities grew 362.3% — significant increase in debt or obligations, assess impact on financial flexibility.
Current assets grew 71.9% — improving short-term liquidity or inventory/receivables build.
Cash position surged 71% — strong cash generation or capital raise providing significant financial cushion.
Current liabilities surged 61.6% — significant near-term obligations; verify ability to meet short-term debt.
Net income declined 55.2% — review whether driven by operations, interest costs, or non-recurring items.
Asset base grew 50.4% — expansion through organic growth, acquisitions, or capital deployment.
Capex reduced 36.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Operating cash flow surged 35.1% — exceptional cash generation, highest quality earnings signal.
Equity decreased 24.5% — buybacks or losses reducing book value, monitor solvency ratios.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →